- Home
- INZY vs VLN Comparison
INZY vs VLN Comparison
Compare INZY & VLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- VLN
- Stock Information
- Founded
- INZY 2015
- VLN 2006
- Country
- INZY United States
- VLN Israel
- Employees
- INZY N/A
- VLN N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- VLN Semiconductors
- Sector
- INZY Health Care
- VLN Technology
- Exchange
- INZY Nasdaq
- VLN Nasdaq
- Market Cap
- INZY 188.2M
- VLN 208.5M
- IPO Year
- INZY 2020
- VLN N/A
- Fundamental
- Price
- INZY $1.36
- VLN $3.35
- Analyst Decision
- INZY Strong Buy
- VLN Strong Buy
- Analyst Count
- INZY 8
- VLN 1
- Target Price
- INZY $17.75
- VLN $4.00
- AVG Volume (30 Days)
- INZY 784.0K
- VLN 1.0M
- Earning Date
- INZY 03-11-2025
- VLN 02-26-2025
- Dividend Yield
- INZY N/A
- VLN N/A
- EPS Growth
- INZY N/A
- VLN N/A
- EPS
- INZY N/A
- VLN N/A
- Revenue
- INZY N/A
- VLN $63,134,000.00
- Revenue This Year
- INZY N/A
- VLN N/A
- Revenue Next Year
- INZY N/A
- VLN $28.20
- P/E Ratio
- INZY N/A
- VLN N/A
- Revenue Growth
- INZY N/A
- VLN N/A
- 52 Week Low
- INZY $1.32
- VLN $1.67
- 52 Week High
- INZY $7.80
- VLN $3.50
- Technical
- Relative Strength Index (RSI)
- INZY 20.27
- VLN 72.29
- Support Level
- INZY $1.32
- VLN $2.82
- Resistance Level
- INZY $3.18
- VLN $3.50
- Average True Range (ATR)
- INZY 0.27
- VLN 0.29
- MACD
- INZY -0.15
- VLN 0.07
- Stochastic Oscillator
- INZY 2.15
- VLN 90.07
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About VLN Valens Semiconductor Ltd.
Valens Semiconductor Ltd is a provider of semiconductor products, pushing the boundaries of connectivity by enabling long-reach, high-speed video, and data transmission for the audio-video and automotive industries. It operates in two segments: Audio-Video, which includes the company's HDBaseT solutions for the Audio-Video market deliver superior, plug-and-play convergence and distribution of different interfaces, through a single long-distance category cable; and Automotive segment products enable safe and resilient high-speed in-vehicle connectivity for car architectures, realizing the vision of connected and autonomous cars. The company's geographical revenue is derived from Hungary.